High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction

Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). Early prediction of adverse effects based on the pharmacokinetics of afatinib enables support for quality of life (QOL)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2021-07, Vol.13 (14), p.3425
Hauptverfasser: Takahashi, Takayuki, Terazono, Hideyuki, Suetsugu, Takayuki, Sugawara, Hideki, Arima, Junko, Nitta, Mina, Tanabe, Toru, Okutsu, Kayu, Ikeda, Ryuji, Mizuno, Keiko, Inoue, Hiromasa, Takeda, Yasuo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 14
container_start_page 3425
container_title Cancers
container_volume 13
creator Takahashi, Takayuki
Terazono, Hideyuki
Suetsugu, Takayuki
Sugawara, Hideki
Arima, Junko
Nitta, Mina
Tanabe, Toru
Okutsu, Kayu
Ikeda, Ryuji
Mizuno, Keiko
Inoue, Hiromasa
Takeda, Yasuo
description Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). Early prediction of adverse effects based on the pharmacokinetics of afatinib enables support for quality of life (QOL) in patients with no change in efficacy. We examined the pharmacokinetic relationship between trough plasma concentration and adverse effects and evaluated the utility of measuring the trough plasma concentration of afatinib as the first EGFR-TKI treatment for NSCLC in a prospective multicenter study. Twenty-four patients treated with afatinib were enrolled in this study. All blood samples were collected at the trough point, and plasma concentrations were measured using high-performance liquid chromatography–tandem mass spectrometry. Logistic regression analysis for the dose reduction of afatinib was performed, and the receiver operating characteristic (ROC) curve was plotted. Although all patients started afatinib at 40 mg/day, plasma concentrations were variable, and mean and median trough plasma concentrations were 32.9 ng/mL and 32.5 ng/mL in this study, respectively. Minimum and maximum trough plasma concentrations were 10.4 ng/mL and 72.7 ng/mL, respectively. This variability was speculated to involve personal parameters such as laboratory data. However, no patient characteristics or laboratory data examined correlated with the trough plasma concentration of afatinib, except albumin. Albumin showed a weak correlation with plasma concentration (r = 0.60, p = 0.009). The trough plasma concentration of afatinib was significantly associated with the dose reduction of afatinib (p = 0.047). The area under the ROC curve (AUC) for the trough plasma concentration of afatinib was 0.81. The cut-off value was 21.4 ng/mL. The sensitivity and specificity of the cut-off as a risk factor were 0.80 and 0.75. In summary, the trough plasma concentration of afatinib was associated with continued or reduced dosage because of the onset of several adverse effects, and a threshold was seen. Adverse effects not only lower QOL but also hinder continued treatment. Measuring plasma concentrations of afatinib appears valuable to predict adverse effects and continue effective therapy.
doi_str_mv 10.3390/cancers13143425
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8305619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2554461559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-4a1ab5038bcb076a97ed5cdae5b7fe300e65ea45005e8d97b81719b699b3fcc3</originalsourceid><addsrcrecordid>eNpdkc9LwzAUx4MobsydvQa8eKlLmiZpLsKYPzYYKrJ7SNJ0y-iambSK_70tG6J7l_fgffjwHl8ArjG6I0SgiVG1sSFigjOSpfQMDFPE04QxkZ3_mQdgHOMWdUUI5oxfgkGHi5wRPgQvc7feJKvg2_UGvlUq7hSc-c5bN0E1ztfQl3BadmPtNFxEOI3RG6caW8Av12zgg48WvtuiNT19BS5KVUU7PvYRWD09rmbzZPn6vJhNl4khad4kmcJKU0RybTTiTAluC2oKZanmpSUIWUatyihC1OaF4DrHHAvNhNCkNIaMwP1Bu2_1zhaHayu5D26nwrf0ysn_m9pt5Np_ypwgyrDoBLdHQfAfrY2N3LlobFWp2vo2ypRSihGhPO3QmxN069tQd9_1VJYxTGkvnBwoE3yMwZa_x2Ak-7TkSVrkB3mGiDs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554461559</pqid></control><display><type>article</type><title>High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Takahashi, Takayuki ; Terazono, Hideyuki ; Suetsugu, Takayuki ; Sugawara, Hideki ; Arima, Junko ; Nitta, Mina ; Tanabe, Toru ; Okutsu, Kayu ; Ikeda, Ryuji ; Mizuno, Keiko ; Inoue, Hiromasa ; Takeda, Yasuo</creator><creatorcontrib>Takahashi, Takayuki ; Terazono, Hideyuki ; Suetsugu, Takayuki ; Sugawara, Hideki ; Arima, Junko ; Nitta, Mina ; Tanabe, Toru ; Okutsu, Kayu ; Ikeda, Ryuji ; Mizuno, Keiko ; Inoue, Hiromasa ; Takeda, Yasuo</creatorcontrib><description>Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). Early prediction of adverse effects based on the pharmacokinetics of afatinib enables support for quality of life (QOL) in patients with no change in efficacy. We examined the pharmacokinetic relationship between trough plasma concentration and adverse effects and evaluated the utility of measuring the trough plasma concentration of afatinib as the first EGFR-TKI treatment for NSCLC in a prospective multicenter study. Twenty-four patients treated with afatinib were enrolled in this study. All blood samples were collected at the trough point, and plasma concentrations were measured using high-performance liquid chromatography–tandem mass spectrometry. Logistic regression analysis for the dose reduction of afatinib was performed, and the receiver operating characteristic (ROC) curve was plotted. Although all patients started afatinib at 40 mg/day, plasma concentrations were variable, and mean and median trough plasma concentrations were 32.9 ng/mL and 32.5 ng/mL in this study, respectively. Minimum and maximum trough plasma concentrations were 10.4 ng/mL and 72.7 ng/mL, respectively. This variability was speculated to involve personal parameters such as laboratory data. However, no patient characteristics or laboratory data examined correlated with the trough plasma concentration of afatinib, except albumin. Albumin showed a weak correlation with plasma concentration (r = 0.60, p = 0.009). The trough plasma concentration of afatinib was significantly associated with the dose reduction of afatinib (p = 0.047). The area under the ROC curve (AUC) for the trough plasma concentration of afatinib was 0.81. The cut-off value was 21.4 ng/mL. The sensitivity and specificity of the cut-off as a risk factor were 0.80 and 0.75. In summary, the trough plasma concentration of afatinib was associated with continued or reduced dosage because of the onset of several adverse effects, and a threshold was seen. Adverse effects not only lower QOL but also hinder continued treatment. Measuring plasma concentrations of afatinib appears valuable to predict adverse effects and continue effective therapy.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13143425</identifier><identifier>PMID: 34298637</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Albumin ; Creatinine ; Diarrhea ; Dosage ; Enzyme inhibitors ; Epidermal growth factor ; Epidermal growth factor receptors ; High-performance liquid chromatography ; Laboratories ; Mass spectroscopy ; Mucositis ; Mutation ; Non-small cell lung carcinoma ; Patients ; Pharmacokinetics ; Plasma ; Protein-tyrosine kinase ; Proteins ; Quality of life ; Regression analysis ; Risk factors ; Side effects ; Small cell lung carcinoma ; Stomatitis</subject><ispartof>Cancers, 2021-07, Vol.13 (14), p.3425</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-4a1ab5038bcb076a97ed5cdae5b7fe300e65ea45005e8d97b81719b699b3fcc3</citedby><cites>FETCH-LOGICAL-c328t-4a1ab5038bcb076a97ed5cdae5b7fe300e65ea45005e8d97b81719b699b3fcc3</cites><orcidid>0000-0002-2657-4454 ; 0000-0001-8080-3812</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305619/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305619/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Takahashi, Takayuki</creatorcontrib><creatorcontrib>Terazono, Hideyuki</creatorcontrib><creatorcontrib>Suetsugu, Takayuki</creatorcontrib><creatorcontrib>Sugawara, Hideki</creatorcontrib><creatorcontrib>Arima, Junko</creatorcontrib><creatorcontrib>Nitta, Mina</creatorcontrib><creatorcontrib>Tanabe, Toru</creatorcontrib><creatorcontrib>Okutsu, Kayu</creatorcontrib><creatorcontrib>Ikeda, Ryuji</creatorcontrib><creatorcontrib>Mizuno, Keiko</creatorcontrib><creatorcontrib>Inoue, Hiromasa</creatorcontrib><creatorcontrib>Takeda, Yasuo</creatorcontrib><title>High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction</title><title>Cancers</title><description>Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). Early prediction of adverse effects based on the pharmacokinetics of afatinib enables support for quality of life (QOL) in patients with no change in efficacy. We examined the pharmacokinetic relationship between trough plasma concentration and adverse effects and evaluated the utility of measuring the trough plasma concentration of afatinib as the first EGFR-TKI treatment for NSCLC in a prospective multicenter study. Twenty-four patients treated with afatinib were enrolled in this study. All blood samples were collected at the trough point, and plasma concentrations were measured using high-performance liquid chromatography–tandem mass spectrometry. Logistic regression analysis for the dose reduction of afatinib was performed, and the receiver operating characteristic (ROC) curve was plotted. Although all patients started afatinib at 40 mg/day, plasma concentrations were variable, and mean and median trough plasma concentrations were 32.9 ng/mL and 32.5 ng/mL in this study, respectively. Minimum and maximum trough plasma concentrations were 10.4 ng/mL and 72.7 ng/mL, respectively. This variability was speculated to involve personal parameters such as laboratory data. However, no patient characteristics or laboratory data examined correlated with the trough plasma concentration of afatinib, except albumin. Albumin showed a weak correlation with plasma concentration (r = 0.60, p = 0.009). The trough plasma concentration of afatinib was significantly associated with the dose reduction of afatinib (p = 0.047). The area under the ROC curve (AUC) for the trough plasma concentration of afatinib was 0.81. The cut-off value was 21.4 ng/mL. The sensitivity and specificity of the cut-off as a risk factor were 0.80 and 0.75. In summary, the trough plasma concentration of afatinib was associated with continued or reduced dosage because of the onset of several adverse effects, and a threshold was seen. Adverse effects not only lower QOL but also hinder continued treatment. Measuring plasma concentrations of afatinib appears valuable to predict adverse effects and continue effective therapy.</description><subject>Albumin</subject><subject>Creatinine</subject><subject>Diarrhea</subject><subject>Dosage</subject><subject>Enzyme inhibitors</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>High-performance liquid chromatography</subject><subject>Laboratories</subject><subject>Mass spectroscopy</subject><subject>Mucositis</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Plasma</subject><subject>Protein-tyrosine kinase</subject><subject>Proteins</subject><subject>Quality of life</subject><subject>Regression analysis</subject><subject>Risk factors</subject><subject>Side effects</subject><subject>Small cell lung carcinoma</subject><subject>Stomatitis</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc9LwzAUx4MobsydvQa8eKlLmiZpLsKYPzYYKrJ7SNJ0y-iambSK_70tG6J7l_fgffjwHl8ArjG6I0SgiVG1sSFigjOSpfQMDFPE04QxkZ3_mQdgHOMWdUUI5oxfgkGHi5wRPgQvc7feJKvg2_UGvlUq7hSc-c5bN0E1ztfQl3BadmPtNFxEOI3RG6caW8Av12zgg48WvtuiNT19BS5KVUU7PvYRWD09rmbzZPn6vJhNl4khad4kmcJKU0RybTTiTAluC2oKZanmpSUIWUatyihC1OaF4DrHHAvNhNCkNIaMwP1Bu2_1zhaHayu5D26nwrf0ysn_m9pt5Np_ypwgyrDoBLdHQfAfrY2N3LlobFWp2vo2ypRSihGhPO3QmxN069tQd9_1VJYxTGkvnBwoE3yMwZa_x2Ak-7TkSVrkB3mGiDs</recordid><startdate>20210708</startdate><enddate>20210708</enddate><creator>Takahashi, Takayuki</creator><creator>Terazono, Hideyuki</creator><creator>Suetsugu, Takayuki</creator><creator>Sugawara, Hideki</creator><creator>Arima, Junko</creator><creator>Nitta, Mina</creator><creator>Tanabe, Toru</creator><creator>Okutsu, Kayu</creator><creator>Ikeda, Ryuji</creator><creator>Mizuno, Keiko</creator><creator>Inoue, Hiromasa</creator><creator>Takeda, Yasuo</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2657-4454</orcidid><orcidid>https://orcid.org/0000-0001-8080-3812</orcidid></search><sort><creationdate>20210708</creationdate><title>High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction</title><author>Takahashi, Takayuki ; Terazono, Hideyuki ; Suetsugu, Takayuki ; Sugawara, Hideki ; Arima, Junko ; Nitta, Mina ; Tanabe, Toru ; Okutsu, Kayu ; Ikeda, Ryuji ; Mizuno, Keiko ; Inoue, Hiromasa ; Takeda, Yasuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-4a1ab5038bcb076a97ed5cdae5b7fe300e65ea45005e8d97b81719b699b3fcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Albumin</topic><topic>Creatinine</topic><topic>Diarrhea</topic><topic>Dosage</topic><topic>Enzyme inhibitors</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>High-performance liquid chromatography</topic><topic>Laboratories</topic><topic>Mass spectroscopy</topic><topic>Mucositis</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Plasma</topic><topic>Protein-tyrosine kinase</topic><topic>Proteins</topic><topic>Quality of life</topic><topic>Regression analysis</topic><topic>Risk factors</topic><topic>Side effects</topic><topic>Small cell lung carcinoma</topic><topic>Stomatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takahashi, Takayuki</creatorcontrib><creatorcontrib>Terazono, Hideyuki</creatorcontrib><creatorcontrib>Suetsugu, Takayuki</creatorcontrib><creatorcontrib>Sugawara, Hideki</creatorcontrib><creatorcontrib>Arima, Junko</creatorcontrib><creatorcontrib>Nitta, Mina</creatorcontrib><creatorcontrib>Tanabe, Toru</creatorcontrib><creatorcontrib>Okutsu, Kayu</creatorcontrib><creatorcontrib>Ikeda, Ryuji</creatorcontrib><creatorcontrib>Mizuno, Keiko</creatorcontrib><creatorcontrib>Inoue, Hiromasa</creatorcontrib><creatorcontrib>Takeda, Yasuo</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>Research Library (ProQuest Database)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takahashi, Takayuki</au><au>Terazono, Hideyuki</au><au>Suetsugu, Takayuki</au><au>Sugawara, Hideki</au><au>Arima, Junko</au><au>Nitta, Mina</au><au>Tanabe, Toru</au><au>Okutsu, Kayu</au><au>Ikeda, Ryuji</au><au>Mizuno, Keiko</au><au>Inoue, Hiromasa</au><au>Takeda, Yasuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction</atitle><jtitle>Cancers</jtitle><date>2021-07-08</date><risdate>2021</risdate><volume>13</volume><issue>14</issue><spage>3425</spage><pages>3425-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Afatinib is used to treat non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation as a second-generation EGFR-tyrosine kinase inhibitor (TKI). Early prediction of adverse effects based on the pharmacokinetics of afatinib enables support for quality of life (QOL) in patients with no change in efficacy. We examined the pharmacokinetic relationship between trough plasma concentration and adverse effects and evaluated the utility of measuring the trough plasma concentration of afatinib as the first EGFR-TKI treatment for NSCLC in a prospective multicenter study. Twenty-four patients treated with afatinib were enrolled in this study. All blood samples were collected at the trough point, and plasma concentrations were measured using high-performance liquid chromatography–tandem mass spectrometry. Logistic regression analysis for the dose reduction of afatinib was performed, and the receiver operating characteristic (ROC) curve was plotted. Although all patients started afatinib at 40 mg/day, plasma concentrations were variable, and mean and median trough plasma concentrations were 32.9 ng/mL and 32.5 ng/mL in this study, respectively. Minimum and maximum trough plasma concentrations were 10.4 ng/mL and 72.7 ng/mL, respectively. This variability was speculated to involve personal parameters such as laboratory data. However, no patient characteristics or laboratory data examined correlated with the trough plasma concentration of afatinib, except albumin. Albumin showed a weak correlation with plasma concentration (r = 0.60, p = 0.009). The trough plasma concentration of afatinib was significantly associated with the dose reduction of afatinib (p = 0.047). The area under the ROC curve (AUC) for the trough plasma concentration of afatinib was 0.81. The cut-off value was 21.4 ng/mL. The sensitivity and specificity of the cut-off as a risk factor were 0.80 and 0.75. In summary, the trough plasma concentration of afatinib was associated with continued or reduced dosage because of the onset of several adverse effects, and a threshold was seen. Adverse effects not only lower QOL but also hinder continued treatment. Measuring plasma concentrations of afatinib appears valuable to predict adverse effects and continue effective therapy.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34298637</pmid><doi>10.3390/cancers13143425</doi><orcidid>https://orcid.org/0000-0002-2657-4454</orcidid><orcidid>https://orcid.org/0000-0001-8080-3812</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2021-07, Vol.13 (14), p.3425
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8305619
source MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Albumin
Creatinine
Diarrhea
Dosage
Enzyme inhibitors
Epidermal growth factor
Epidermal growth factor receptors
High-performance liquid chromatography
Laboratories
Mass spectroscopy
Mucositis
Mutation
Non-small cell lung carcinoma
Patients
Pharmacokinetics
Plasma
Protein-tyrosine kinase
Proteins
Quality of life
Regression analysis
Risk factors
Side effects
Small cell lung carcinoma
Stomatitis
title High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T09%3A51%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-Trough%20Plasma%20Concentration%20of%20Afatinib%20Is%20Associated%20with%20Dose%20Reduction&rft.jtitle=Cancers&rft.au=Takahashi,%20Takayuki&rft.date=2021-07-08&rft.volume=13&rft.issue=14&rft.spage=3425&rft.pages=3425-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13143425&rft_dat=%3Cproquest_pubme%3E2554461559%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2554461559&rft_id=info:pmid/34298637&rfr_iscdi=true